Charles River Laboratories International (NYSE:CRL) Releases Earnings Results

Charles River Laboratories International (NYSE:CRL) posted its earnings results on Wednesday. The medical research company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06, Zacks reports. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The firm had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. During the same period last year, the firm earned $2.66 EPS. The company’s quarterly revenue was down .8% on a year-over-year basis. Charles River Laboratories International updated its FY 2026 guidance to 10.700-11.200 EPS.

Charles River Laboratories International Stock Down 3.5%

Shares of NYSE CRL opened at $152.99 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $228.88. The stock has a fifty day moving average price of $202.19 and a 200 day moving average price of $179.58. The company has a market cap of $7.53 billion, a P/E ratio of -98.04, a P/E/G ratio of 4.88 and a beta of 1.63.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently bought and sold shares of CRL. First Manhattan CO. LLC. bought a new stake in Charles River Laboratories International in the fourth quarter worth $2,162,000. Balyasny Asset Management L.P. raised its holdings in Charles River Laboratories International by 37.8% in the 4th quarter. Balyasny Asset Management L.P. now owns 208,559 shares of the medical research company’s stock worth $41,603,000 after acquiring an additional 57,204 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in Charles River Laboratories International by 87.3% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 50,882 shares of the medical research company’s stock valued at $10,150,000 after acquiring an additional 23,720 shares during the period. Abel Hall LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $275,000. Finally, Cetera Investment Advisers grew its holdings in Charles River Laboratories International by 7.6% in the 4th quarter. Cetera Investment Advisers now owns 7,125 shares of the medical research company’s stock valued at $1,421,000 after buying an additional 502 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Barclays lifted their price target on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Robert W. Baird set a $224.00 price target on Charles River Laboratories International in a report on Friday, January 9th. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research report on Monday, December 1st. Finally, Evercore raised their price target on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.